Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated 30 minutes ago
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
30 minutes ago
Latigo Biotherapeutics is preparing to go public in order to bankroll the...
Building a workforce engine for biomanufacturing
30 minutes ago
Ohio’s $30M training initiative aims to scale talent pipelines and power life...
Why early de-risking is redefining the path to IND
30 minutes ago
Lonza explains why early de-risking has become a strategic imperative for biotech...
Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain project
1 day ago
Biotronik Neuro has acquired a portfolio of spinal cord stimulation patents from...
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
3 days ago
Another biotech is squeezing into the crowded IPO waiting room just in...
Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecast
3 days ago
Abbott turned in a stronger than expected second quarter, allaying market concerns...
BIO San Diego 2026 Executive Interviews
3 days ago
Every year, the BIO International Convention brings together more than 20,000 leaders...
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
3 days ago
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease...
Chutes & Ladders—Cue lines up new CMO and research head
3 days ago
Cue Biopharma is tapping in a new chief medical officer and head...
5 emerging biotech hubs
3 days ago
Boston. San Francisco. Beijing? The global biotech industry has long been concentrated...
GSK axes key cough drug candidate after phase 3 data end blockbuster hopes
3 days ago
GSK has ended development of camlipixant in chronic cough after delivering mixed...
Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal
3 days ago
Dimerix has bought an acute kidney injury drug from Mission Therapeutics, paying...